Elicio Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on developing new immunotherapies for cancer. Our work targets cancers such as mutant Kirsten rat sarcoma viral oncogene homolog ("mKRAS")-positive pancreatic cancer, colorectal cancer ("CRC"), lung cancer, and other mKRAS-positive cancers. We aim to create effective, ready-to-use immunotherapies by building on recent successes in personalized cancer immunotherapy. Our unique Amphiphile ("AMP") technology is designed to improve how cancer-specific T cells are trained, activated, and multiplied compared to traditional immunotherapy methods. The goal is to help patients maintain long-lasting immune surveillance against cancer. We believe our AMP technology can produce strong T cell responses in patients, which could lead to significant clinical benefits. We think that many existing and developing cancer immunotherapies are limited because they don't effectively reach lymph nodes or fully interact with the immune cells crucial for adaptive immunity. Our AMP technology is specifically designed to deliver its components to lymph nodes to create a strong T cell response, which we believe is essential for an anti-cancer immune response. Our main programs involve cancer immunotherapy candidates that target specific tumor mutations using common neoantigens. This approach allows for an "off-the-shelf" treatment, meaning patients can receive treatment without delays from manufacturing or the higher costs of personalized immunotherapy. Our clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy in a Phase 2 study. ELI-002 7P is designed to stimulate an immune response against mKRAS pancreatic ductal adenocarcinoma ("PDAC"), the most common type of pancreatic cancer. The ELI-002 7P formulation aims to generate broad immune responses against seven Kirsten rat sarcoma viral oncogene homolog ("KRAS") mutations found in approximately 88% of PDAC patients and 25% of all solid tumors, expanding its potential patient population beyond just PDAC.